Lung Cancer-targeting Adenovirus Vector Construction Service
With the continuous development of molecular biotechnology and the emergence of various biological research tools, gene therapy has become a key area of modern medical research because of its safety and stability. As a leader in the Oncolytic Virotherapyconstruction, Creative Biolabs has established an advanced AV construction platform. Through continuously technical accumulation, we have launched advanced lung cancer-targeted adenoviral vector construction service to provide safe and reliable molecular tools for your research.
Lung Cancer-targeting Gene Therapy
Lung cancer is a malignant tumor with extremely high mortality, which seriously endangers human health. The incidence rate has always been at the forefront of various types of cancer. In the past few decades, medical technology for lung cancer has progressed slowly, and the survival rate of patients with non-small cell lung cancer (NSCLC) has hardly improved; the survival of patients with small-cell lung cancer (SCLC) has been extended with the development of chemotherapy technology, but there have been few cases that are completely cured. Therefore, it is an urgent need for the emergence of new and effective treatments.
Figure 1. The principle of targeted gene expression controlled by a tumor-specific promoter. Specific transcription factors in cancer cells are able to induce therapeutic gene expression. On the other hand, expression of the therapeutic gene is not obtained in normal cells because they lack the specific transcription factors.1
With the gradual maturity of DNA recombination technology and gene transfer technology, gene therapy for lung cancer has become a promising treatment. It targets the molecular characteristics of lung cancer and uses gene transfer technology to introduce foreign genes into tumor cells or other cells to correct or compensate for defective genes. There are many advantages of gene therapy for lung cancer. The broad epithelial cells on the surface of the lungs facilitate the introduction of foreign genes. During the course of treatment, specific receptor cells can be obtained by lung biopsy to observe the therapeutic effect. Therefore, the development of lung cancer' gene therapy is very rapid. For instance, recombinant adenovirus-mediated p53 gene transfer can significantly enhance the drug sensitivity of lung cancer cells. Obviously, it will become a routine treatment in the future.
Adenovirus Vector for Gene Therapy
The most critical and difficult part of gene therapy is the choice of suitable vectors. A good vector must be able to specifically carry the gene of interest to the target organ and express at a certain level for a certain period of time to exert therapeutic effects. Adenoviruses are most widely used in the treatment of lung diseases due to their tendency to the lungs. Adenovirus can not only insert large fragments of DNA, but also infect dividing and resting cells as well as some other cells that the retrovirus cannot infect. Adenovirus can express a large amount of protein independent of the proliferation of host cells, and avoid the inefficiency of treatment due to slow replication of airway epithelial cells. In addition, adenovirus can proliferate itself in the intestines and respiratory tract, so the gene transfer can be carried out through various methods. Intravenous injection of recombinant virus, and making the recombinant virus into a capsule or a drug are both effective. Oral administration or spraying is easier to popularize. In gene therapy, a recombinant AV supplemented with a cytomegalovirus promoter can specifically express E2F-1 in NSCLC, demonstrating a good therapeutic effect in clinical trials.
Why Lung Cancer Requires Targeted Gene Delivery Strategies?
Complex Tumor Biology and Heterogeneity
Lung cancer is characterized by significant genetic and phenotypic heterogeneity, including mutations in EGFR, KRAS, ALK, and other oncogenic drivers. This diversity complicates treatment and necessitates highly tailored therapeutic approaches capable of selectively targeting malignant cells.
Tumor Microenvironment Barriers
The lung tumor microenvironment is highly immunosuppressive and includes stromal barriers that hinder efficient drug delivery. In addition, the respiratory system's exposure to environmental factors increases the risk of non-specific viral infection in normal tissues.
Limitations of Conventional Viral Vectors
Traditional adenoviral vectors face several limitations:
- Non-specific infection of healthy lung epithelial cells
- Rapid clearance by the immune system
- Insufficient tumor penetration and retention
These challenges underscore the importance of tumor-targeted adenoviral engineering to improve delivery precision and therapeutic outcomes.
Adenovirus Vectors: A Versatile Platform for Lung Cancer Gene Therapy
Adenoviral vectors are widely used in gene therapy due to their unique advantages:
- High transgene expression efficiency
- Ability to infect both dividing and non-dividing cells
- Episomal expression without genomic integration
- Large genetic payload capacity
Mechanism of Oncolytic Adenovirus
Oncolytic adenoviruses are engineered to selectively replicate within tumor cells, leading to:
- Tumor cell lysis and viral amplification
- Release of progeny viruses to infect neighboring tumor cells
- Activation of anti-tumor immune responses
This dual mechanism—direct oncolysis and immune activation—makes adenoviruses particularly attractive for lung cancer therapy.
Flexible Therapeutic Payloads
Our adenoviral systems support diverse therapeutic strategies, including:
- Tumor suppressor genes
- Suicide genes
- Immunomodulatory cytokines
- Combination therapeutic constructs
Our Services
At Creative Biolabs, we provide a comprehensive suite of lung cancer-targeting adenovirus vector construction services designed to support your research and therapeutic development from concept to validation. Our integrated capabilities enable precise vector engineering, efficient delivery, and robust functional performance tailored specifically for lung cancer applications.
Custom Adenovirus Vector Design
We offer fully customized adenoviral vector design based on your specific research objectives:
- Selection of optimal adenoviral backbone (e.g., Ad5 or modified serotypes)
- Incorporation of tumor-specific promoters (e.g., hTERT, survivin, COX-2)
Our team works closely with you to ensure that each vector is precisely aligned with your experimental or therapeutic goals.
Capsid Engineering and Targeting Optimization
To enhance tumor specificity and transduction efficiency, we provide advanced capsid modification strategies:
- Fiber knob modification for receptor-specific targeting
- Peptide ligand insertion (e.g., EGFR, integrin targeting)
- CAR-independent infection strategies
- Retargeting to lung cancer-specific surface markers
These approaches significantly improve selective infection of tumor cells while minimizing off-target effects.
Oncolytic Adenovirus Development
We specialize in the construction of replication-selective oncolytic adenoviruses:
- Tumor-specific replication control via promoter engineering
- Conditional replication systems
- Armed oncolytic viruses expressing therapeutic payloads
- Dual-targeting designs for enhanced selectivity
Our oncolytic platforms are designed to maximize tumor lysis and stimulate anti-tumor immunity.
Therapeutic Gene Insertion and Optimization
We support the integration and optimization of a wide range of therapeutic payloads:
- Tumor suppressor genes
- Suicide genes
- Immunomodulatory factors
- Combination gene expression systems
We ensure stable expression, high functionality, and compatibility with your vector system.
Adenovirus Packaging, Amplification, and Purification
Our production services ensure high-quality viral preparations:
- High-efficiency virus packaging in appropriate cell systems
- Large-scale amplification
- Purification using industry-standard methods
- Endotoxin-free, high-purity preparations
We deliver ready-to-use viral particles suitable for downstream applications.
Applications of Adenovirus Vector Construction
Our lung cancer-targeting adenovirus vector construction service is designed to support a broad spectrum of research applications. By integrating precise tumor-targeting strategies with flexible genetic engineering, our solutions enable researchers and developers to accelerate innovation across multiple areas of lung cancer biology and treatment.
Oncolytic Virotherapy Development
We engineer replication-competent adenoviruses capable of selectively infecting and lysing lung cancer cells. These oncolytic vectors:
- Induce direct tumor cell destruction
- Amplify therapeutic effects through viral replication
- Trigger systemic anti-tumor immune responses
This approach is particularly valuable for developing next-generation virotherapies targeting NSCLC and SCLC.
Targeted Gene Replacement Therapy
Our vectors can be designed to deliver functional genes into tumor cells to restore normal cellular pathways. Applications include:
- Tumor suppressor gene delivery (e.g., p53 restoration)
- Correction of dysregulated signaling pathways
- Functional studies of gene roles in lung cancer progression
- This enables both therapeutic development and mechanistic research.
Cancer Immunotherapy Enhancement
We support the development of immuno-gene therapy strategies by constructing adenoviruses expressing immune-modulating molecules, such as:
- Cytokines
- Immune checkpoint regulators
- Tumor-specific antigens
These vectors can enhance immune cell infiltration and activation within the tumor microenvironment, improving response rates to immunotherapies.
Lung Cancer Model Development and Validation
We provide tools for establishing and validating lung cancer research models:
- Gene-modified cell line development
- Tumor-targeting validation systems
- Functional assays for therapeutic evaluation
These applications support both early-stage discovery and preclinical validation.
Our Workflow
We believe in a collaborative, phase-gated approach that provides clarity and control at every step.
-
Phase 1: Consultation & Design
Our team of PhD-level scientists works with you to understand your research goals, target genes, and experimental model. We co-develop the optimal vector strategy, including serotype, promoter, and any specialized modifications.
-
Phase 2: Vector Construction & Cloning
We employ state-of-the-art molecular biology techniques, including AdEasy and Gateway-based systems, for rapid and accurate cloning of your transgene into the adenoviral backbone. Full sequencing data is provided for your records.
-
Phase 3: Virus Production & Amplification
Following successful cloning, the vector is transfected into our production cell lines. We then perform a small-scale test amplification to confirm functionality before scaling up to your required titer and volume.
-
Phase 4: Purification & Quality Control
The bulk virus harvest is purified using our proprietary chromatography and density gradient methods. The final, concentrated product undergoes our full suite of quality control assays, including titer determination, purity analysis, and sterility testing.
-
Phase 5: Validation (Optional Value-Added Service)
To accelerate your project, we offer an optional in vitro functional validation. This includes testing the vector's transduction efficiency in a panel of lung cancer cell lines and confirming target gene expression via Western blot, qPCR, or functional assay as per your specifications.
-
Phase 6: Delivery & Expert Support
You receive your purified, titered, and fully documented vector with a comprehensive technical report. Our support continues post-delivery, with expert consultation on applications ranging from in vitro mechanistic studies to in vivo animal model dosing.
Validation of Lung Cancer-targeted Adenovirus
To ensure robust performance, we provide comprehensive validation services.
Expression Validation
- qPCR analysis of transgene expression
- Western blot and protein quantification
- Reporter gene assays
Functional Validation
- Cytotoxicity assays
- Apoptosis and cell viability analysis
- Viral replication assays
Tumor Targeting Evaluation
We assess specificity and efficacy using:
- Lung cancer cell lines (e.g., A549, H1299)
- Normal lung epithelial controls
- Xenograft tumor models (optional)
Why Choose Our Lung Cancer-Targeting Adenovirus Vectors?
Choosing the right vector is the most consequential decision in gene therapy development. Our service is built on a foundation of specialized expertise, providing distinct advantages that translate directly to research success.
01. Unmatched Targeting Precision for Lung Cancer
Lung cancer presents unique challenges, including cellular heterogeneity and the need for localized, potent action. We design vectors to meet these challenges head-on.
- Optimized Serotype Selection: Leveraging our extensive library, we help you select the optimal adenovirus serotype (e.g., Ad5, Ad11, or chimeric variants) based on the tropism for your specific lung cancer cell lines (NSCLC, SCLC) and primary cells.
- Tissue-Specific Promoters: Enhance safety and specificity by incorporating promoters that restrict transgene expression to lung cancer cells.
- Targeted Transduction: For applications requiring enhanced cellular entry, we can engineer vectors with fiber modifications or bispecific adaptors to target known lung cancer biomarkers such as EGFR, EpCAM, or folate receptors.
02. High-Yield, High-Purity Production for Reproducible Results
Inconsistent vector quality is a leading cause of irreproducible research. Our advanced production platform ensures you receive a product you can trust.
- Advanced Production Systems: We utilize high-expression cell lines and optimized culture conditions to achieve industry-leading viral titers.
- Superior Purification: Our multi-step purification process, combining cesium chloride density gradient ultracentrifugation with advanced chromatographic methods, removes empty capsids, host cell proteins, and residual DNA. This yields vectors with a purity >99%, minimizing off-target effects and immune responses in vivo.
-
Stringent Quality Control: Every vector lot undergoes a rigorous QC battery, including:
- Physical Titer: A260/A280 ratio analysis
- Functional Titer: TCID50 or plaque assay
- Sterility & Mycoplasma Testing
- Replication Competent Adenovirus (RCA) Testing
- Genomic Integrity Verification: Restriction mapping and sequencing
03. Full Customization from Gene to Delivery
We offer a true end-to-end service, accommodating your most complex experimental designs.
- Gene of Interest: Cloning of therapeutic genes, reporter genes, or CRISPR-Cas9 components.
- Vector Modifications: Design of first-generation, gutless, or oncolytic adenoviruses.
- Formulation: Tailored buffer formulations for optimal stability in your experimental system, be it in vitro cell culture or in vivo systemic administration.
Frequently Asked Questions (FAQ)
Q: What is the maximum transgene capacity of your adenovirus vectors?
A: For our first-generation (E1/E3 deleted) vectors, the maximum insert size is approximately 8.0 kb. For larger transgenes or multiple gene cassettes, we recommend our helper-dependent (gutless) adenovirus system, which can accommodate up to 36 kb.
Q: Can you provide vectors for in vivo studies in immunocompetent mouse models?
A: Yes. For studies requiring delivery to immunocompetent animals, we recommend using species-specific serotypes or chimeric capsid vectors that are not neutralized by human pre-existing immunity. We can also provide vectors pseudotyped to evade the mouse immune response. This is a core part of our consultation process.
Q: How long does a typical project take?
A: A standard adenovirus vector construction project, from cloning to purified and titered final product, is typically completed in 6–8 weeks. Accelerated timelines are available for urgent projects and can be discussed during the initial consultation.
Q: What information do you need to provide a quote?
A: To provide the most accurate quote, please share the following: 1) The sequence of your gene of interest, 2) Desired vector serotype, 3) Preferred promoter, 4) Any required tags or reporter genes, and 5) The total quantity and titer required for your experiments. Our team will respond with a detailed proposal within 24 business hours.
Q: Do you offer validation services?
A: Absolutely. We offer a comprehensive suite of optional validation services to de-risk your project. This includes in vitro transduction efficiency studies in your chosen cell lines, transgene expression analysis (qPCR, Western Blot), and functional assays to confirm biological activity.
Creative Biolabs provides you with high-quality adenoviral vectors as a tool for gene delivery in vivo and in vitro. Our vectors are more specific, safer and more stable. The construction of a vector targeting lung cancer will continue to be the focus of our work for a long time in the future, and we look forward to establishing a long-term cooperative relationship with you. If you have any questions or have any difficulties, you can contact us by email or send us an inquiry to find a complete solution.
Reference
- Montaño-Samaniego M, Bravo-Estupiñan D M, Méndez-Guerrero O, et al. Strategies for targeting gene therapy in cancer cells with tumor-specific promoters. Frontiers in oncology, 2020, 10: 605380. https://doi.org/10.3389/fonc.2020.605380 Distributed under Open Access license CC BY 4.0, without modification.
